PureTech Health Announces Voluntary Delisting of American Depositary Shares

PureTech Health announced that it has notified Nasdaq of its intention to voluntarily delist its American depositary shares, each representing the right to receive 10 ordinary shares of the company. Following the effectiveness of the delisting, PureTech's ordinary shares will remain listed on the London Stock Exchange, which will continue to serve as the company's primary trading venue. Following a review of the company's listing structure and shareholder trading patterns, the board of directors determined that maintaining a dual listing is no longer necessary. The substantial majority of trading volume, liquidity, and price discovery for PureTech's shares occurs on the LSE, and the majority of the company's current investor base as well as the company's governance framework are centered in the United Kingdom. Following the delisting, and until such time as PureTech may consider terminating its American depositary receipt program, PureTech expects its ADSs to be quoted and traded on the over-the-counter market via a sponsored Level 1 ADR program. No action is required to be taken by ADS holders at this time.